HEART FAILURE WITH MIDRANGE EJECTION FRACTION

This adverse event was reported 59 times

These drugs are most commonly taken by patients reporting HEART FAILURE WITH MIDRANGE EJECTION FRACTION:

# Drug Count
0 CYCLOPHOSPHAMIDE 20
1 CYCLOPHOSPHAMIDE FOR INJECTION 20
2 CYCLOPHOSPHAMIDE INJECTION, SOLUTION 20
3 TRASTUZUMAB 18
4 DOXORUBICIN 15
5 DOCETAXEL 11
6 DOCETAXEL ANHYDROUS 11
7 BUSULFAN 10
8 CARBOPLATIN 10
9 CISPLATIN 10
See all common drugs associated with HEART FAILURE WITH MIDRANGE EJECTION FRACTION

HEART FAILURE WITH MIDRANGE EJECTION FRACTION is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 TOPOTECAN HYDROCHLORIDE 8 0.0033
1 THIOTEPA 10 0.0010
2 BUSULFAN 10 0.0006
3 ADO-TRASTUZUMAB EMTANSINE 5 0.0006
4 MELPHALAN HYDROCHLORIDE 10 0.0004
5 TOPOTECAN 2 0.0003
6 FAM-TRASTUZUMAB DERUXTECAN-NXKI 3 0.0003
7 VINCRISTINE SULFATE 8 0.0003
8 TRASTUZUMAB 18 0.0003
9 GLUCAGON 1 0.0002
See all drugs enriched for association with HEART FAILURE WITH MIDRANGE EJECTION FRACTION

HEART FAILURE WITH MIDRANGE EJECTION FRACTION is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 HER2/neu Receptor Antagonist [EPC] 20 0.0003
1 Antihypoglycemic Agent [EPC] 1 0.0002
2 Topoisomerase Inhibitor [EPC] 10 0.0001
3 Sigma-1 Agonist [EPC] 1 0.0001
4 Alkylating Drug [EPC] 22 0.0001
5 Alkaloid [EPC] 2 0.0001
6 Microtubule Inhibitor [EPC] 11 0.0001
7 Anticholinergic [EPC] 1 0.0001
8 Programmed Death Ligand-1 Blocker [EPC] 1 0.0000
9 Platinum-based Drug [EPC] 10 0.0000
See all drug classes enriched for association with HEART FAILURE WITH MIDRANGE EJECTION FRACTION